Specific serotonin (5HT3) receptor antagonist. Prepn: I. H. Coates et al., EP 191562; eidem, US 4695578 (1986, 1987 both to Glaxo). Pharmacology: A. Butler et al., Br. J. Pharmacol. 94, 397 (1988). LC-MS/MS determn in plasma: Y. Dotsikas et al., J. Chromatogr. B 836, 79 (2006). Clinical trials in cancer chemotherapy-induced nausea and vomiting: M. G. Kris et al., J. Clin. Oncol. 6, 659 (1988); L. Cubeddu et al., N. Engl. J. Med. 322, 810 (1990); M. Marty et al., ibid. 816. Clinical evaluation in treatment of bulimia: P. L. Faris et al., Lancet 355, 792 (2000); in early onset alcoholism: B. A. Johnson et al., J. Am. Med. Assoc. 284, 963 (2000); in radiotherapy-induced nausea and emesis: J. P. LeBourgeois et al., Clin. Oncol. 11, 340 (1999). Review of pharmacology and therapeutic use: A. Markham, E. M. Sorkin, Drugs 45, 931-952 (1993); of clinical pharmacokinetics: K. H. Simpson, F. M. Hicks, J. Pharm. Pharmacol. 48, 774-781 (1996).
Antiemetic.
Antiemetic; Serotonin Receptor Antagonist